CO2018004684A2 - Métodos para tratar la epilepsia - Google Patents
Métodos para tratar la epilepsiaInfo
- Publication number
- CO2018004684A2 CO2018004684A2 CONC2018/0004684A CO2018004684A CO2018004684A2 CO 2018004684 A2 CO2018004684 A2 CO 2018004684A2 CO 2018004684 A CO2018004684 A CO 2018004684A CO 2018004684 A2 CO2018004684 A2 CO 2018004684A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- nonsense mutation
- treat epilepsy
- epileptic disease
- treating
- Prior art date
Links
- 206010015037 epilepsy Diseases 0.000 title 1
- 108020004485 Nonsense Codon Proteins 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000001037 epileptic effect Effects 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 3
- 230000037434 nonsense mutation Effects 0.000 abstract 3
- DGFURIPMSCLLMY-UHFFFAOYSA-N 2-(1,2,4-oxadiazol-3-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1=NOC=N1 DGFURIPMSCLLMY-UHFFFAOYSA-N 0.000 abstract 1
- 102100034746 Cyclin-dependent kinase-like 5 Human genes 0.000 abstract 1
- 201000007547 Dravet syndrome Diseases 0.000 abstract 1
- 101000945692 Homo sapiens Cyclin-dependent kinase-like 5 Proteins 0.000 abstract 1
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 abstract 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 abstract 1
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 abstract 1
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562248891P | 2015-10-30 | 2015-10-30 | |
| PCT/US2016/059262 WO2017075312A1 (en) | 2015-10-30 | 2016-10-28 | Methods for treating epilepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018004684A2 true CO2018004684A2 (es) | 2018-08-10 |
Family
ID=58632013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0004684A CO2018004684A2 (es) | 2015-10-30 | 2018-04-30 | Métodos para tratar la epilepsia |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10517853B2 (enExample) |
| EP (1) | EP3368042A4 (enExample) |
| JP (1) | JP2018531975A (enExample) |
| KR (1) | KR20180081516A (enExample) |
| CN (1) | CN108348527A (enExample) |
| AR (1) | AR106530A1 (enExample) |
| BR (1) | BR112018008838A8 (enExample) |
| CA (1) | CA3003132A1 (enExample) |
| CO (1) | CO2018004684A2 (enExample) |
| HK (1) | HK1251965A1 (enExample) |
| IL (1) | IL258988A (enExample) |
| MX (1) | MX2018005361A (enExample) |
| PH (1) | PH12018500885A1 (enExample) |
| TW (1) | TW201729807A (enExample) |
| WO (1) | WO2017075312A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108603230A (zh) | 2015-10-09 | 2018-09-28 | 南安普敦大学 | 基因表达的调节与蛋白质表达失调的筛选 |
| CN116059236A (zh) | 2015-12-14 | 2023-05-05 | 冷泉港实验室 | 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体 |
| KR20260009385A (ko) | 2017-08-25 | 2026-01-19 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| JP2021523227A (ja) | 2018-05-04 | 2021-09-02 | ストーク セラピューティクス，インク． | コレステリルエステル蓄積症の処置のための方法及び組成物 |
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| US11301527B2 (en) * | 2019-05-06 | 2022-04-12 | Acto Technologies Inc. | Event-driven content recommendation engine |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| US12624011B2 (en) * | 2020-03-17 | 2026-05-12 | Sumitomo Pharma Co., Ltd. | Oxadiazole derivative |
| US12338437B2 (en) | 2020-05-11 | 2025-06-24 | Stoke Therapeutics, Inc. | OPA1 antisense oligomers for treatment of conditions and diseases |
| CN117987538A (zh) * | 2024-04-07 | 2024-05-07 | 北京诺禾致源科技股份有限公司 | 用于检测depdc5突变基因的试剂在制备诊断或预测家族性局灶性癫痫伴可变灶1型的试剂盒中的应用 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL291628A (enExample) | 1962-04-17 | |||
| US4022901A (en) | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
| US4016170A (en) | 1975-07-28 | 1977-04-05 | Sandoz, Inc. | Oxadiazolyl benzamides |
| US4135910A (en) | 1977-05-12 | 1979-01-23 | Monsanto Company | Oxadiazol-3-yl-benzoates as plant growth regulants |
| US4166732A (en) | 1977-05-12 | 1979-09-04 | Monsanto Company | Oxadiazol-5-yl-benzoates |
| US4210762A (en) | 1978-08-17 | 1980-07-01 | Monsanto Company | 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates |
| US4268299A (en) | 1978-08-17 | 1981-05-19 | Monsanto Company | Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates |
| US5484944A (en) | 1993-10-27 | 1996-01-16 | Neurogen Corporation | Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands |
| TW343965B (en) | 1994-03-30 | 1998-11-01 | Hoffmann La Roche | Novel mono- and bicyclic DNA gyrase inhibitors |
| US6071700A (en) | 1995-01-20 | 2000-06-06 | University Of Massachusetts | Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions |
| EP0853626A1 (en) | 1995-09-07 | 1998-07-22 | Novartis AG | Substituted phosphinic compounds and their use as pharmaceuticals |
| WO1997041105A1 (en) | 1996-04-26 | 1997-11-06 | Nippon Soda Co., Ltd. | Novel heterocycle-substituted benzene derivatives and herbicides |
| DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| US6034106A (en) | 1996-06-07 | 2000-03-07 | Merck & Co., Inc. | Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity |
| JP2000511903A (ja) | 1996-06-07 | 2000-09-12 | メルク エンド カンパニー インコーポレーテッド | 糖尿病および肥満の治療のための選択性β▲下３▼作動薬としてのオキサジアゾール・ベンゼンスルホンアミド |
| DE19626318A1 (de) | 1996-07-01 | 1998-01-08 | Basf Ag | Farbstoffmischungen, enthaltend Polyazofarbstoffe |
| ZA98371B (en) | 1997-01-31 | 1999-07-16 | Du Pont | Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides. |
| ES2329739T3 (es) | 1997-04-07 | 2009-11-30 | Georgetown University | Analogos de cocaina. |
| US6004933A (en) | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
| AU9647998A (en) | 1997-10-27 | 1999-05-17 | Nippon Soda Co., Ltd. | Novel benzoylpyrazole derivatives and herbicides |
| IL139187A0 (en) | 1998-04-23 | 2001-11-25 | Cortech Inc | Cysteine protease inhibitors |
| CA2346689A1 (en) | 1998-10-08 | 2000-04-20 | Gregor James Macdonald | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| EP1119568B1 (en) | 1998-10-09 | 2004-02-18 | Janssen Pharmaceutica N.V. | 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
| EP1126833A4 (en) | 1998-10-29 | 2004-09-08 | Trega Biosciences Inc | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES CONTAINING THESE DERIVATIVES |
| BR9916488A (pt) | 1998-12-23 | 2001-10-09 | Smithkline Beecham Corp | Inibidores de protease |
| AU3196200A (en) | 1999-03-26 | 2000-10-16 | Shionogi & Co., Ltd. | Beta-amino acid derivatives |
| WO2000058304A1 (en) | 1999-03-26 | 2000-10-05 | Shionogi & Co., Ltd. | Heterocyclic sulfonamide derivatives |
| WO2000058280A1 (en) | 1999-03-26 | 2000-10-05 | Shionogi & Co., Ltd. | Carbocyclic sulfonamide derivatives |
| AU4537900A (en) | 1999-05-17 | 2000-12-05 | Agouron Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
| UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
| JP2001247569A (ja) | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | ピロリジン誘導体又はピペリジン誘導体及びその医薬用途 |
| US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| WO2001066534A2 (en) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
| US6498151B2 (en) | 2000-03-22 | 2002-12-24 | Merck Frosst Canada & Co. | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors |
| AU2001248765A1 (en) | 2000-04-21 | 2001-11-12 | Shionogi And Co., Ltd. | Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders |
| GB0011089D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (11) |
| DZ3347A1 (fr) | 2000-05-22 | 2001-11-29 | Aventis Pharma Inc | Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase |
| JP2002105073A (ja) | 2000-09-27 | 2002-04-10 | Shionogi & Co Ltd | 新規マトリックスメタロプロテアーゼ阻害剤 |
| AUPR362001A0 (en) | 2001-03-08 | 2001-04-05 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| CA2342432A1 (en) | 2001-03-28 | 2002-09-28 | Christopher Norbert Johnson | Novel compound |
| GB0108102D0 (en) | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
| BR0209054A (pt) | 2001-04-19 | 2004-04-20 | Bayer Ag | Arilsulfonamidas como agentes antivirais |
| US7041685B2 (en) | 2001-06-08 | 2006-05-09 | Cytovia, Inc. | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| JP2003081832A (ja) | 2001-06-26 | 2003-03-19 | Takeda Chem Ind Ltd | レチノイド関連受容体機能調節剤 |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| MY151199A (en) | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
| CN1691944A (zh) | 2002-08-09 | 2005-11-02 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体－5调节剂的噁二唑 |
| AU2003264018A1 (en) | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| AU2003901425A0 (en) * | 2003-03-27 | 2003-04-10 | Bionomics Limited | A diagnostic method for epilepsy |
| JP2006521344A (ja) | 2003-03-28 | 2006-09-21 | ファイザー・プロダクツ・インク | アテローム性動脈硬化症および肥満の治療のためのｃｅｔｐ阻害剤としての１，２，４−置換１，２，３，４−テトラヒドロ−および１，２−ジヒドロ−キノリンおよび１，２，３，４−テトラヒドロ−キノキサリン誘導体 |
| EP4101846B1 (en) | 2003-04-11 | 2023-08-02 | PTC Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| US20050075375A1 (en) | 2003-05-14 | 2005-04-07 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis C virus |
| WO2005060961A2 (en) | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd) |
| US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| JP2008515992A (ja) | 2004-10-13 | 2008-05-15 | ピーティーシー セラピューティクス，インコーポレーテッド | 体細胞変異に起因する疾患の阻止／治療用医薬を製造するための規定化合物の使用 |
| AU2006235115C1 (en) | 2005-04-08 | 2013-02-28 | Ptc Therapeutics, Inc. | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
| CN101193632A (zh) * | 2005-04-08 | 2008-06-04 | Ptc医疗公司 | 用于无义突变抑制治疗的口服活性1,2,4-噁二唑组合物 |
| US20100088778A1 (en) * | 2005-06-16 | 2010-04-08 | John Charles Mulley | Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A Gene |
| EP2387995A1 (en) | 2006-03-30 | 2011-11-23 | PTC Therapeutics, Inc. | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith |
| WO2007123848A2 (en) | 2006-04-19 | 2007-11-01 | Brown University | Therapeutic compositions containing modified class i slrp proteins |
| NZ598012A (en) | 2006-09-08 | 2013-08-30 | Ptc Therapeutics Inc | Processes for the preparation of 1,2,4-oxadiazole benzoic acids |
| UA99600C2 (en) | 2006-09-25 | 2012-09-10 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
| US8101641B2 (en) | 2006-09-25 | 2012-01-24 | Ptc Therapeutics, Inc. | Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof |
| KR20170100072A (ko) | 2006-10-12 | 2017-09-01 | 피티씨 테라퓨틱스, 인크. | 넌센스 돌연변이 억제 치료를 위한 경구 활성 1,2,4-옥사디아졸의 투여 방법 |
| WO2008127364A2 (en) | 2006-10-13 | 2008-10-23 | Myriad Genetics, Inc. | Antiviral compounds and use thereof |
| US20110177999A1 (en) | 2007-08-09 | 2011-07-21 | Vertex Pharmaceuticals Incorporated | Therapeutic Combinations Useful in Treating CFTR Related Diseases |
| CN101970420B (zh) | 2007-10-04 | 2014-09-24 | 默克雪兰诺有限公司 | 噁二唑衍生物 |
| NZ584793A (en) | 2007-10-26 | 2012-05-25 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| EP2234625B8 (en) | 2007-12-17 | 2013-10-30 | The Regents of the University of Michigan | Compositions and methods for treating and preventing skeletal muscle deficiencies |
| WO2010008831A2 (en) | 2008-06-24 | 2010-01-21 | Irm Llc | Compounds and methods for modulating g protein-coupled receptors |
| AU2009302478B2 (en) | 2008-10-07 | 2015-09-03 | Horizon Orphan Llc | Aerosol fluoroquinolone formulations for improved pharmacokinetics |
| RU2398770C1 (ru) | 2009-03-27 | 2010-09-10 | Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) | Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота |
| EP2241558A1 (en) * | 2009-04-03 | 2010-10-20 | Merck Serono SA | Oxadiazole derivatives |
| WO2011072281A1 (en) | 2009-12-11 | 2011-06-16 | Ptc Therapeutics, Inc. | Methods for treating methylmalonic acidemia |
| JP5877200B2 (ja) * | 2010-08-05 | 2016-03-02 | ユニヴェルシテ ドゥ ドロワ エ サンテ ドゥ リール | ナンセンス突然変異による疾患の治療に有用な化合物及びその化合物を含む医薬組成物 |
| WO2015134711A1 (en) | 2014-03-06 | 2015-09-11 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
| WO2015188037A1 (en) | 2014-06-06 | 2015-12-10 | Ptc Therapeutics, Inc. | Methods of treatment using a 1,2,4-oxadiazole benzoic acid |
-
2016
- 2016-10-28 TW TW105135155A patent/TW201729807A/zh unknown
- 2016-10-28 HK HK18111236.1A patent/HK1251965A1/zh unknown
- 2016-10-28 KR KR1020187013165A patent/KR20180081516A/ko not_active Withdrawn
- 2016-10-28 JP JP2018522022A patent/JP2018531975A/ja active Pending
- 2016-10-28 CN CN201680063273.8A patent/CN108348527A/zh active Pending
- 2016-10-28 AR ARP160103314A patent/AR106530A1/es unknown
- 2016-10-28 CA CA3003132A patent/CA3003132A1/en not_active Abandoned
- 2016-10-28 BR BR112018008838A patent/BR112018008838A8/pt not_active Application Discontinuation
- 2016-10-28 US US15/771,379 patent/US10517853B2/en active Active
- 2016-10-28 WO PCT/US2016/059262 patent/WO2017075312A1/en not_active Ceased
- 2016-10-28 EP EP16860855.2A patent/EP3368042A4/en not_active Withdrawn
- 2016-10-28 MX MX2018005361A patent/MX2018005361A/es unknown
-
2018
- 2018-04-25 PH PH12018500885A patent/PH12018500885A1/en unknown
- 2018-04-26 IL IL258988A patent/IL258988A/en unknown
- 2018-04-30 CO CONC2018/0004684A patent/CO2018004684A2/es unknown
-
2019
- 2019-11-07 US US16/676,806 patent/US20200188362A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180081516A (ko) | 2018-07-16 |
| US20200188362A1 (en) | 2020-06-18 |
| MX2018005361A (es) | 2018-06-07 |
| US20180333397A1 (en) | 2018-11-22 |
| JP2018531975A (ja) | 2018-11-01 |
| EP3368042A4 (en) | 2019-06-26 |
| CN108348527A (zh) | 2018-07-31 |
| BR112018008838A2 (pt) | 2018-11-06 |
| BR112018008838A8 (pt) | 2019-02-26 |
| EP3368042A1 (en) | 2018-09-05 |
| TW201729807A (zh) | 2017-09-01 |
| CA3003132A1 (en) | 2017-05-04 |
| US10517853B2 (en) | 2019-12-31 |
| PH12018500885A1 (en) | 2018-10-29 |
| WO2017075312A1 (en) | 2017-05-04 |
| HK1251965A1 (zh) | 2019-05-10 |
| AR106530A1 (es) | 2018-01-24 |
| IL258988A (en) | 2018-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016001715A1 (es) | Nuevos inhibidores de glutaminasa | |
| CO2017005034A2 (es) | Tratamiento de convulsiones con fosfatasa alcalina recombinante | |
| DOP2017000271A (es) | Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t | |
| CR20160582A (es) | Composición para tratar diabetes, que contienen un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada | |
| MX392014B (es) | Composiciones y métodos para modular la expresión de angiotensinógeno. | |
| PH12018500885A1 (en) | Methods for treating epilepsy | |
| CL2019001214A1 (es) | Composición farmacéutica, métodos para tratamiento y sus usos. | |
| MX388325B (es) | Metodos de diagnostico para tratamiento con linfocitos t. | |
| PE20180260A1 (es) | Metodos y kits para tratar la depresion | |
| CL2015000699A1 (es) | Métodos para tratamiento de cáncer. | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| BR112016010454A2 (pt) | métodos para tratar uma taupatia | |
| NI201500150A (es) | TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método | |
| CL2017002242A1 (es) | Método para tratar un tumor cerebral | |
| MX2017004558A (es) | Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos. | |
| CL2015003343A1 (es) | Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico. | |
| CO7160102A2 (es) | Fármaco para prevenir y/o tratar la enfermedad renal poliquística | |
| WO2016094834A3 (en) | A method for treating a complement mediated disorder caused by an infectious agent in a patient | |
| BR112019005040A2 (pt) | aplicação de pridopidina para tratamento de síndrome de rett | |
| MX387658B (es) | Métodos para tratar y/o prevenir queratosis actínica. | |
| MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
| MX2020002762A (es) | Composiciones y métodos para tratar una lesión cerebral. | |
| MX2020003243A (es) | Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada. | |
| MY203831A (en) | Treatment and diagnosis of inflammatory disorders | |
| AR102871A1 (es) | Métodos de tratamiento de fibrosis |